MLICM
IBRX icon

Metropolitan Life Insurance Company (MetLife)’s ImmunityBio IBRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,038
Closed -$32.4K – 1003
2024
Q1 		$32.4K Sell
6,038
-1,644
-21% -$7.44K ﹤0.01% 1624
2023
Q4 		$38.6K Buy
7,682
+1,622
+27% +$5.09K ﹤0.01% 1588
2023
Q3 		$10.2K Hold
6,060
– – ﹤0.01% 2194
2023
Q2 		$16.8K Buy
6,060
+1,470
+32% +$4.16K ﹤0.01% 2020
2023
Q1 		$8.35K Sell
4,590
-363
-7% -$1.13K ﹤0.01% 2219
2022
Q4 		$25.1K Hold
4,953
– – ﹤0.01% 1884
2022
Q3 		$24.6K Buy
4,953
+3,109
+169% +$14.2K ﹤0.01% 1913
2022
Q2 		$6.86K Sell
1,844
-2,805
-60% -$11.3K ﹤0.01% 2332
2022
Q1 		$26.1K Sell
4,649
-14,225
-75% -$87.3K ﹤0.01% 1964
2021
Q4 		$115K Sell
18,874
-329
-2% -$2.47K ﹤0.01% 2394
2021
Q3 		$187K Hold
19,203
– – ﹤0.01% 2130
2021
Q2 		$274K Buy
19,203
+9,732
+103% +$161K ﹤0.01% 1930
2021
Q1 		$225K Sell
9,471
-300
-3% -$7.78K ﹤0.01% 1936
2020
Q4 		$130K Hold
9,771
– – ﹤0.01% 2213
2020
Q3 		$67.8K Hold
9,771
– – ﹤0.01% 2417
2020
Q2 		$120K Buy
+9,771
New +$55.2K ﹤0.01% 2139
2017
Q3 		– Sell
-23,692
Closed -$180K – 2496
2017
Q2 		$180K Buy
+23,692
New +$102K ﹤0.01% 2399

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IBRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 6,038 shares — an estimated $32.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IBRX in Q2 2017 and held it in 17 quarters. The position peaked at $274K in Q2 2021. 194 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,038 ImmunityBio shares in Q2 2024, an estimated $32.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in ImmunityBio in Q2 2017 and held it in 17 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s ImmunityBio position peaked at $274K in Q2 2021.
  • 194 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.